A subset of flavaglines inhibits KRAS nanoclustering and activation

• Main Authors: Yurugi, Hajime, Zhuang, Yinyin, Siddiqui, Farid A., Liang, Hong, Rosigkeit, Sebastian, Zeng, Yongpeng, Abou-Hamdan, Hussein, Bockamp, Ernesto, Zhou, Yong, Abankwa, Daniel, Zhao, Wenting, Désaubry, Laurent, Rajalingam, Krishnaraj
• Other Authors: School of Chemical and Biomedical Engineering
• Format: Article
• Language: English
• Published: 2021
• Subjects: Engineering::Bioengineering; KRAS; Phospholipid
• Online Access: https://hdl.handle.net/10356/149025
• Institution: Nanyang Technological University

The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loa...